Sales dropped 6.2% to $536.9 million compared with $572.6 million for the second quarter of 2019. In particular, revenues in the company's clinical diagnostics segment decreased by 20.7%.

However, net income for Q2 was $966.4 million versus $598.8 million in the second quarter of 2019 primarily due to the recognition of changes in the fair market value of equity securities related to the holdings of Bio-Rad Laboratories' investment in Sartorius.

Year-to-date net income reached $1.65 billion compared with $1.46 billion for the same period last year. Given the situation with the pandemic, the firm thinks its third quarter 2020 year-over-year currency-neutral sales may be flat to up 5%.

Bio-Rad posts increased Q1 revenue during pandemic
For the quarter revenue increased to $571.6 million, compared with $554 million in the first quarter of 2019. Meanwhile, net income in the first...

Bio-Rad acquires single-cell analysis company
Bio-Rad Laboratories has acquired Celsee, a company that offers instruments and consumables for single-cell analysis.